Cytokine modulation and suppression of liver injury by a novel analogue of thalidomide (Q44193390)

30 November 2017

Cytokine modulation and suppression of liver injury by a novel analogue of thalidomide (English)

1 reference

30 November 2017

0 references

8

1 reference

30 November 2017

7

Gisa Tiegs

0 references

Manuela Rossol

4

object named as

Manuela Rossol

0 references

author name string

Andrea Thiele

1

1 reference

30 November 2017

Renate Bang

2

1 reference

30 November 2017

Michael Gütschow

3

1 reference

30 November 2017

Manuela Rossol

4

1 reference

30 November 2017

Sebastian Loos

5

1 reference

30 November 2017

Kurt Eger

6

1 reference

30 November 2017

Gisa Tiegs

7

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

European Journal of Pharmacology

30 November 2017

1 reference

30 November 2017

453

1 reference

30 November 2017

2-3

1 reference

30 November 2017

325-334

1 reference

Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902423-8

Thalidomide is an inhibitor of angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902423-8

Mode of action of anti-lipopolysaccharide-binding protein antibodies for prevention of endotoxemic shock in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902423-8

Phenotypical and functional characterization of Fc gamma receptor I (CD64)-negative monocytes, a minor human monocyte subpopulation with high accessory and antiviral activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902423-8

Aza analogues of thalidomide: synthesis and evaluation as inhibitors of tumor necrosis factor-alpha production in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902423-8

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902423-8

Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902423-8

Depletion of hepatic glutathione prevents death receptor-dependent apoptotic and necrotic liver injury in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902423-8

Combined effects of insulin and dexamethasone on cyclic AMP phosphodiesterase 3 and glycogen metabolism in cultured rat hepatocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902423-8

The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902423-8

Hepatoprotective role of interleukin 10 in galactosamine/lipopolysaccharide mouse liver injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902423-8

Determination of lymphocyte division by flow cytometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902423-8

Immunotherapeutic and antitumour potential of thalidomide analogues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902423-8

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902423-8

Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902423-8

Thalidomide analogs and PDE4 inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902423-8

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902423-8

Enhanced potency of perfluorinated thalidomide derivatives for inhibition of LPS-induced tumor necrosis factor-alpha production is associated with a change of mechanism of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902423-8

Up-regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902423-8

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902423-8

The Influence of Thalidomide on the Clinical and Immunologic Manifestation of Erythema Nodosum Leprosum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902423-8

Thalidomide: rationale for renewed use in immunological disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902423-8

Tumor necrosis factor is a terminal mediator in galactosamine/endotoxin-induced hepatitis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902423-8

Thalidomide for the treatment of chronic graft-versus-host disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902423-8

Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2902423-8

10.1016/S0014-2999(02)02423-8

7 January 2021

Identifiers

DOI

1 reference

30 November 2017

1 reference